Clinical Trial Detail
| NCT ID | NCT02654587 |
| Title | Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | OSE Immunotherapeutics |
| Indications | |
| Therapies | |
| Age Groups: | adult senior |
CKB BOOST